血清胸苷激酶1在健康体检中的应用

Serum thymidine kinase 1 measurement in health check-up

目的评估血清胸苷激酶1（STKl）在健康体检人群中的临床应用价值。方法选取健康体检人群8896例，采用高灵敏度点印染／免疫增强发光检测系统（ECL）进行STKl浓度测定，同时与常规体检平行进行。结果以2pmol／L为阈值，阳性组STKl水平为（5．474-4．23）pmol／L，明显高于阴性组（0．624-0．48）pmol／L（t=11．90，P=0．00）。STKl水平高低无性别相关性，但与年龄老化有关，STKl阳性组平均年龄（48．2±12．0）岁，STKl阴性组平均年龄（41．8±12．3）岁（t=5．37，P=0．00）。STKl阳性率为1．2％（108／8896），其中疾病包括：恶性肿瘤治疗前／后1．9％，癌前病变／良性肿瘤27．8％，非肿瘤增殖性疾病36．0％，乙型肝炎（乙肝）／幽门螺旋杆菌（HP）感染14．8％，脂肪肝10．2％，其他疾病占9．3％，与肿瘤没有直接或间接联系，STKl预示可能渐变为癌症的风险为90．7％。STKl阴性组未筛查出恶性肿瘤和癌前病变，而恶性肿瘤治疗后、良性肿瘤、非肿瘤增殖性疾病在与STKl阳性组相应疾病比较中，差异均有统计学意义（P〈0．05）。结论STKl能真实评估体内细胞异常增殖情况，适用于体检人群早期肿瘤风险筛查。对于STKl阳性者，需对导致STKl增高的其他非肿瘤因素进行排查，同时体检者要定期监测，以便尽可能给予预防治疗和早期诊断。

Objective To evaluate the utility of serum thymidine kinase 1 （STK1） in health screening. Methods A total of 8896 adults who participated in heahh check-up during November 2009 and November 2010 were tested for STK1 by using sensitive chemiluminescence＇s dot blot assay. Results The level of STK1 of group A （ STK1 〉 2 pmol/L） was much higher than that of the group B （ STK1 〈 2 pmol/L） [ （ 5.47± 4. 23 ） vs （0. 62 ± 0. 48 ） pmol/L ; t = 11.90, P = 0.00 ]. The STK1 level was not correlated with gender. However,the mean age of individuals in the group A was higher than that in the group B E （48.2 ± 12. 0） vs （41.8 ± 12. 3 ） years; t = 5.37,P = O. 00 ]. The positive detection rate of STK1 was 1.2% （ 108/ 8896）. In the group A,there were 1.9% preor post-treatment malignancy,27.8% pre-malignant tumor or benign disease, 36. 0% nontumorous proliferation disease, 14. 8% hepatitis B virus/HP infection, 10. 2% fatty liver, and 9. 3% other diseases. No pretreatment malignancy and premalignancy were found in the group B. Conclusion STK1 measurement could reflect the situation of cell proliferation and predict the risk of any type of malignancy.